Jazz Pharmaceuticals PLC Company Profile (NASDAQ:JAZZ)

About Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Jazz Pharmaceuticals PLC logoJazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:JAZZ
  • CUSIP: G5087110
  • Web: www.jazzpharma.com
Capitalization:
  • Market Cap: $9.66 billion
  • Outstanding Shares: 60,091,000
Average Prices:
  • 50 Day Moving Avg: $153.65
  • 200 Day Moving Avg: $142.97
  • 52 Week Range: $95.80 - $163.75
P/E:
  • Trailing P/E Ratio: 24.35
  • Foreward P/E Ratio: 12.32
  • P/E Growth: 0.81
Sales & Book Value:
  • Annual Revenue: $1.53 billion
  • Price / Sales: 6.32
  • Book Value: $33.05 per share
  • Price / Book: 4.87
Profitability:
  • EBIDTA: $760.64 million
  • Net Margins: 26.28%
  • Return on Equity: 24.65%
  • Return on Assets: 9.96%
Debt:
  • Debt-to-Equity Ratio: 0.88%
  • Current Ratio: 1.92%
  • Quick Ratio: 1.82%
Misc:
  • Average Volume: 440,776 shs.
  • Beta: 1.11
  • Short Ratio: 3.05
 
Frequently Asked Questions for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

What is Jazz Pharmaceuticals PLC's stock symbol?

Jazz Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "JAZZ."

How were Jazz Pharmaceuticals PLC's earnings last quarter?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) issued its earnings results on Tuesday, May, 9th. The company reported $1.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.42 by $0.01. The company earned $376.10 million during the quarter, compared to analyst estimates of $376.58 million. Jazz Pharmaceuticals PLC had a net margin of 26.28% and a return on equity of 24.65%. The company's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.26 EPS. View Jazz Pharmaceuticals PLC's Earnings History.

What guidance has Jazz Pharmaceuticals PLC issued on next quarter's earnings?

Jazz Pharmaceuticals PLC issued an update on its FY17 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of $10.70-11.30 for the period, compared to the Thomson Reuters consensus estimate of $11.13. The company issued revenue guidance of $1.625-1.700, compared to the consensus revenue estimate of $1.67 billion.

Where is Jazz Pharmaceuticals PLC's stock going? Where will Jazz Pharmaceuticals PLC's stock price be in 2017?

17 brokerages have issued twelve-month target prices for Jazz Pharmaceuticals PLC's stock. Their forecasts range from $150.00 to $210.00. On average, they anticipate Jazz Pharmaceuticals PLC's stock price to reach $184.94 in the next year. View Analyst Ratings for Jazz Pharmaceuticals PLC.

What are analysts saying about Jazz Pharmaceuticals PLC stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals PLC stock:

  • 1. Cantor Fitzgerald analysts commented, "Meetings highlight view that late-stage assets are underappreciated. We hosted meetings with the CEO in the Midwest last week. Investors he met with expressed interest in Xyrem, of course, but the bulk of the questions centered around the pipeline. A common theme was that JZP-110 may be underestimated by the Street. We also spoke with some investors who seem to be gaining appreciation for the potential of the low-sodium oxybate formulations. Vyxeos approval could be around the corner. The PDUFA date for Vyxeos is September 30, and management commented that Breakthrough-designated drugs have been approved before the statutory date." (6/27/2017)
  • 2. According to Zacks Investment Research, "Jazz’s missed estimates for earnings and sales in the first quarter of 2017. The company’s sleep disorder drug, Xyrem, is the only FDA-approved product for both cataplexy and EDS. However, Xyrem is facing patent challenges. Jazz has also been facing challenges in building sufficient inventory levels for leukemia drug Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions this year. However, its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. In Oct 2016, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, which was completed in early Apr 2017. Jazz’ shares outperformed the industry so far this year." (5/15/2017)
  • 3. Mizuho analysts commented, "We raise our PT to $162 from $152 while reiterating our Buy rating following positive Phase III data in a key pipeline drug (JZP-110) in obstructive sleep apnea. Our PT went up due to increased likelihood of FDA approval." (3/21/2017)
  • 4. Cowen and Company analysts commented, "complete re-rating."Cacciatore comments, "We continue to believe Jazz is nearing a very interesting inflection point, as a favorable resolution to the Xyrem litigation is likely, which could extend the franchise to 2024/2025. Combined with JZP-110's potential $750MM+ opportunity to complement growing Defitelio, Erwinaze, and ultimately Vyxeos, we believe a complete re-rating is nearing. We would add here." (3/20/2017)
  • 5. BMO Capital Markets analysts commented, "JAZZ delivered on an important milestone with positive Phase 3 data for JZP-110 in two OSA studies that appear to demonstrate a very solid clinical profile for this novel wake-promoting agent. There had been some concerns into these data (first OSA studies for JZP-110), and we think this outcome significantly de-risks the program; Phase 3 data in narcolepsy set for 2Q17 and filing in late 2017. We reiterate our Outperform; JAZZ remains a top pick." (3/20/2017)

Are investors shorting Jazz Pharmaceuticals PLC?

Jazz Pharmaceuticals PLC saw a increase in short interest in the month of June. As of June 15th, there was short interest totalling 1,835,939 shares, an increase of 64.9% from the May 31st total of 1,113,578 shares. Based on an average trading volume of 500,285 shares, the days-to-cover ratio is presently 3.7 days. Currently, 3.2% of the shares of the stock are short sold.

Who are some of Jazz Pharmaceuticals PLC's key competitors?

Who owns Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include APG Asset Management N.V. (0.46%), Bank of Montreal Can (0.08%), Livforsakringsbolaget Skandia Omsesidigt (0.04%), Gateway Investment Advisers LLC (0.03%), Tealwood Asset Management Inc. (0.03%) and Cardan Capital Partners LLC (0.03%). Company insiders that own Jazz Pharmaceuticals PLC stock include Bruce C Cozadd, Heather Ann Mcsharry, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Michael Patrick Miller, Patrick G Enright, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals PLC.

Who sold Jazz Pharmaceuticals PLC stock? Who is selling Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, APG Asset Management N.V., Cardan Capital Partners LLC, Independent Portfolio Consultants Inc., Aperio Group LLC, Xact Kapitalforvaltning AB, Creative Planning and Tealwood Asset Management Inc.. Company insiders that have sold Jazz Pharmaceuticals PLC stock in the last year include Bruce C Cozadd, Karen J Wilson, Michael Patrick Miller, Patrick G Enright, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.

Who bought Jazz Pharmaceuticals PLC stock? Who is buying Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock was acquired by a variety of institutional investors in the last quarter, including Mn Services Vermogensbeheer B.V., Eqis Capital Management Inc., US Bancorp DE and Somerset Trust Co. Company insiders that have bought Jazz Pharmaceuticals PLC stock in the last two years include Karen L Smith and Kenneth W O'keefe. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.

How do I buy Jazz Pharmaceuticals PLC stock?

Shares of Jazz Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jazz Pharmaceuticals PLC's stock price today?

One share of Jazz Pharmaceuticals PLC stock can currently be purchased for approximately $160.98.


MarketBeat Community Rating for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  636 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  825
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $184.94 (14.88% upside)

Analysts' Ratings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017Deutsche Bank AGSet Price TargetBuy$174.00 -> $178.00LowView Rating Details
7/14/2017Piper Jaffray CompaniesSet Price TargetBuy$182.00LowView Rating Details
7/14/2017Cowen and CompanyReiterated RatingBuy$190.00LowView Rating Details
7/4/2017MizuhoDowngradeBuy -> Neutral$162.00 -> $150.00LowView Rating Details
7/4/2017Leerink SwannBoost Price TargetBuy$169.00 -> $170.00LowView Rating Details
7/4/2017Janney Montgomery ScottBoost Price TargetNeutral -> Buy$138.00 -> $175.00LowView Rating Details
6/27/2017Royal Bank Of CanadaSet Price TargetBuy$210.00N/AView Rating Details
6/27/2017Cantor FitzgeraldReiterated RatingBuy$197.00MediumView Rating Details
6/12/2017J P Morgan Chase & CoReiterated RatingOverweight$190.00LowView Rating Details
6/7/2017BMO Capital MarketsBoost Price TargetOutperform$192.00 -> $196.00MediumView Rating Details
5/22/2017Sanford C. BernsteinSet Price TargetMarket Perform$160.00 -> $176.00LowView Rating Details
3/1/2017Stifel NicolausLower Price TargetBuy$200.00 -> $190.00N/AView Rating Details
2/22/2017Evercore ISIInitiated CoverageBuy$160.00N/AView Rating Details
2/16/2017GuggenheimReiterated RatingBuyN/AView Rating Details
1/19/2017SunTrust Banks, Inc.Reiterated RatingBuy$210.00N/AView Rating Details
1/18/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$170.00N/AView Rating Details
1/18/2017Barclays PLCReiterated RatingOverweight$200.00N/AView Rating Details
6/18/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
4/5/2016Canaccord GenuityReiterated RatingBuy$170.00N/AView Rating Details
4/1/2016Northland SecuritiesReiterated RatingOutperform$175.00N/AView Rating Details
(Data available from 7/24/2015 forward)

Earnings

Earnings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Earnings by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Earnings History by Quarter for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017$1.42$1.41$376.58 million$376.10 millionViewListenView Earnings Details
2/28/2017Q416$2.65$1.91$398.91 million$396.62 millionViewListenView Earnings Details
11/8/2016Q316$2.61$2.16$389.34 million$374.00 millionViewListenView Earnings Details
8/9/2016Q216$2.80$2.63$376.40 million$381.00 millionViewN/AView Earnings Details
5/10/2016Q1$2.31$2.26$338.86 million$336.00 millionViewListenView Earnings Details
2/23/2016Q415$2.60$2.60$349.98 million$340.90 millionViewListenView Earnings Details
11/9/2015Q315$2.56$2.52$348.15 million$340.90 millionViewListenView Earnings Details
8/5/2015Q215$2.41$2.41$335.58 million$333.70 millionViewListenView Earnings Details
5/7/2015Q115$2.15$1.99$309.50 million$309.30 millionViewListenView Earnings Details
2/24/2015Q414$2.30$2.44$319.74 million$328.10 millionViewListenView Earnings Details
11/4/2014Q314$1.98$2.33$302.90 million$306.58 millionViewListenView Earnings Details
8/5/2014Q214$1.92$2.05$273.39 million$291.23 millionViewListenView Earnings Details
5/8/2014Q114$1.79$1.61$254.86 million$247.00 millionViewListenView Earnings Details
2/25/2014Q413$1.78$1.72$238.12 million$235.80 millionViewListenView Earnings Details
11/5/2013Q313$1.67$1.78$227.38 million$232.20 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.52$1.43$208.71 million$208.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.35$1.37$189.92 million$196.20 millionViewListenView Earnings Details
2/26/2013Q4 2012$1.41$1.53$183.80 million$183.70 millionViewListenView Earnings Details
11/8/2012Q312$1.31$1.29$178.57 million$175.50 millionViewN/AView Earnings Details
8/7/2012$1.05$1.09ViewN/AView Earnings Details
5/8/2012$0.90$0.91ViewN/AView Earnings Details
11/1/2011$0.89$0.94ViewN/AView Earnings Details
7/28/2011$0.67$0.82ViewN/AView Earnings Details
5/3/2011$0.57$0.59ViewN/AView Earnings Details
3/7/2011$0.60$0.63ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172$1.89$2.84$2.37
Q3 20171$2.47$2.47$2.47
Q4 20171$2.78$2.78$2.78
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 86.28%
Insider Trades by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Insider Trades by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/20/2017Suzanne Sawochka HooperEVPSell4,580$160.00$732,800.00View SEC Filing  
7/17/2017Michael Patrick MillerEVPSell200$154.97$30,994.00View SEC Filing  
6/23/2017Suzanne Sawochka HooperEVPSell420$160.00$67,200.00View SEC Filing  
6/15/2017Michael Patrick MillerEVPSell200$150.65$30,130.00View SEC Filing  
6/1/2017Rick E WinninghamDirectorSell5,000$150.00$750,000.00View SEC Filing  
5/15/2017Michael Patrick MillerEVPSell200$152.98$30,596.00View SEC Filing  
5/11/2017Bruce C CozaddCEOSell30,000$153.47$4,604,100.00View SEC Filing  
5/9/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.00View SEC Filing  
4/27/2017Karen J WilsonSVPSell1,275$160.00$204,000.00View SEC Filing  
4/27/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.00View SEC Filing  
4/17/2017Michael Patrick MillerSVPSell200$152.56$30,512.00View SEC Filing  
4/11/2017Bruce C CozaddCEOSell1,000$152.12$152,120.00View SEC Filing  
4/10/2017Karen J WilsonSVPSell11,458$152.24$1,744,365.92View SEC Filing  
3/15/2017Michael Patrick MillerSVPSell200$137.89$27,578.00View SEC Filing  
3/6/2017Paul TreacySVPSell884$131.97$116,661.48View SEC Filing  
2/15/2017Michael Patrick MillerSVPSell200$134.55$26,910.00View SEC Filing  
1/18/2017Russell J. CoxCOOSell4,000$128.75$515,000.00View SEC Filing  
1/17/2017Michael Patrick MillerSVPSell200$115.93$23,186.00View SEC Filing  
12/15/2016Michael Patrick MillerSVPSell200$103.09$20,618.00View SEC Filing  
12/2/2016Patrick G EnrightDirectorSell677$101.80$68,918.60View SEC Filing  
11/15/2016Michael Patrick MillerSVPSell200$112.19$22,438.00View SEC Filing  
11/14/2016Kenneth W O'keefeDirectorBuy2,000$113.84$227,680.00View SEC Filing  
10/17/2016Michael Patrick MillerSVPSell200$118.16$23,632.00View SEC Filing  
9/19/2016Michael Patrick MillerSVPSell200$126.17$25,234.00View SEC Filing  
8/25/2016Seamus MulliganDirectorSell27,968$128.32$3,588,853.76View SEC Filing  
8/16/2016Paul TreacySVPSell1,292$137.47$177,611.24View SEC Filing  
8/15/2016Michael Patrick MillerSVPSell100$136.45$13,645.00View SEC Filing  
8/15/2016Rick E WinninghamDirectorSell633$136.45$86,372.85View SEC Filing  
8/12/2016Karen L SmithInsiderBuy608$137.10$83,356.80View SEC Filing  
8/9/2016Bruce C. CozaddCEOSell1,000$150.00$150,000.00View SEC Filing  
8/9/2016Russell J. CoxCOOSell4,000$148.66$594,640.00View SEC Filing  
7/15/2016Michael Patrick MillerSVPSell100$142.43$14,243.00View SEC Filing  
7/13/2016Karen L SmithCMOBuy580$143.63$83,305.40View SEC Filing  
6/15/2016Michael Patrick MillerSVPSell100$149.64$14,964.00View SEC Filing  
6/13/2016Karen L SmithCMOBuy557$149.61$83,332.77View SEC Filing  
5/16/2016Heather Ann McsharryDirectorSell697$145.20$101,204.40View SEC Filing  
5/16/2016Michael Patrick MillerSVPSell100$145.20$14,520.00View SEC Filing  
4/25/2016Karen J WilsonSVPSell604$160.00$96,640.00View SEC Filing  
4/15/2016Michael Patrick MillerSVPSell100$145.79$14,579.00View SEC Filing  
4/13/2016Karen J WilsonSVPSell5,007$150.00$751,050.00View SEC Filing  
4/12/2016Russell J CoxCOOSell4,000$136.98$547,920.00View SEC Filing  
4/7/2016Karen J WilsonSVPSell2,161$140.90$304,484.90View SEC Filing  
3/15/2016Michael Patrick MillerSVPSell100$129.17$12,917.00View SEC Filing  
3/8/2016Bruce C CozaddCEOSell2,500$126.04$315,100.00View SEC Filing  
2/29/2016Paul TreacySVPSell354$123.48$43,711.92View SEC Filing  
2/23/2016Seamus MulliganDirectorSell27,968$122.71$3,431,953.28View SEC Filing  
2/16/2016Michael Patrick MillerSVPSell100$115.63$11,563.00View SEC Filing  
2/10/2016Patrick G EnrightDirectorSell10,000$117.92$1,179,200.00View SEC Filing  
2/9/2016Bruce C CozaddCEOSell2,500$111.37$278,425.00View SEC Filing  
1/15/2016Michael Patrick MillerSVPSell100$122.66$12,266.00View SEC Filing  
1/12/2016Bruce C CozaddCEOSell2,500$123.81$309,525.00View SEC Filing  
1/5/2016Patrick G EnrightDirectorSell10,000$138.09$1,380,900.00View SEC Filing  
12/15/2015Michael Patrick MillerSVPSell100$136.99$13,699.00View SEC Filing  
12/8/2015Bruce C CozaddCEOSell2,500$139.72$349,300.00View SEC Filing  
12/2/2015Patrick G EnrightDirectorSell10,424$146.67$1,528,888.08View SEC Filing  
11/23/2015Seamus MulliganDirectorSell27,968$145.86$4,079,412.48View SEC Filing  
11/10/2015Bruce C CozaddCEOSell2,500$128.53$321,325.00View SEC Filing  
11/10/2015Patrick G EnrightDirectorSell10,000$135.29$1,352,900.00View SEC Filing  
10/21/2015Suzanne Sawochka HooperEVPSell2,000$125.00$250,000.00View SEC Filing  
10/13/2015Bruce C CozaddCEOSell2,500$131.50$328,750.00View SEC Filing  
10/5/2015Patrick G EnrightDirectorSell10,000$133.79$1,337,900.00View SEC Filing  
9/25/2015Michael Patrick MillerSVPSell100$145.23$14,523.00View SEC Filing  
9/8/2015Bruce C. CozaddCEOSell2,500$163.07$407,675.00View SEC Filing  
9/1/2015Patrick G EnrightDirectorSell10,000$165.99$1,659,900.00View SEC Filing  
7/14/2015Bruce C CozaddCEOSell5,000$177.79$888,950.00View SEC Filing  
7/14/2015Suzanne Sawochka HooperEVPSell4,000$177.79$711,160.00View SEC Filing  
7/6/2015Patrick G EnrightDirectorSell10,000$177.11$1,771,100.00View SEC Filing  
6/9/2015Bruce C CozaddCEOSell5,000$173.16$865,800.00View SEC Filing  
6/9/2015Suzanne Sawochka HooperEVPSell4,000$173.16$692,640.00View SEC Filing  
6/2/2015Karen J WilsonSVPSell5,751$179.59$1,032,822.09View SEC Filing  
6/1/2015Karen J WilsonSVPSell5,494$179.57$986,557.58View SEC Filing  
4/14/2015Bruce C CozaddCEOSell5,000$181.45$907,250.00View SEC Filing  
4/14/2015Suzanne Sawochka HooperEVPSell4,000$181.45$725,800.00View SEC Filing  
3/25/2015Seamus MulliganDirectorSell50,000$174.59$8,729,500.00View SEC Filing  
1/5/2015Patrick G EnrightDirectorSell10,000$160.25$1,602,500.00View SEC Filing  
12/26/2014Seamus MulliganDirectorSell50,000$163.40$8,170,000.00View SEC Filing  
12/12/2014Patrick G EnrightDirectorSell2,343$170.98$400,606.14View SEC Filing  
12/9/2014Bruce C CozaddCEOSell5,000$178.79$893,950.00View SEC Filing  
12/9/2014Suzanne Sawochka HooperEVPSell1,852$178.79$331,119.08View SEC Filing  
12/1/2014Patrick G EnrightDirectorSell10,000$172.74$1,727,400.00View SEC Filing  
11/24/2014Jeffrey K TobiasCMOSell4,598$170.12$782,211.76View SEC Filing  
11/7/2014Iain McgillSVPSell7,066$172.03$1,215,563.98View SEC Filing  
10/10/2014Jeffrey K TobiasCMOSell1,000$154.04$154,040.00View SEC Filing  
10/6/2014Patrick G EnrightDirectorSell10,000$160.56$1,605,600.00View SEC Filing  
9/25/2014Seamus MulliganDirectorSell50,000$163.16$8,158,000.00View SEC Filing  
9/24/2014Seamus MulliganDirectorSell35,294$163.70$5,777,627.80View SEC Filing  
9/12/2014Jeffrey K TobiasCMOSell1,000$171.22$171,220.00View SEC Filing  
9/11/2014Karen J WilsonSVPSell3,000$175.00$525,000.00View SEC Filing  
9/11/2014Seamus MulliganDirectorSell50,000$175.00$8,750,000.00View SEC Filing  
9/9/2014Bruce C CozaddCEOSell5,000$170.32$851,600.00View SEC Filing  
9/8/2014Karen J WilsonSVPSell2,500$170.00$425,000.00View SEC Filing  
9/8/2014Suzanne Sawochka HooperEVPSell1,852$168.00$311,136.00View SEC Filing  
8/12/2014Bruce C CozaddCEOSell5,000$133.15$665,750.00View SEC Filing  
8/12/2014Suzanne Sawochka HooperEVPSell1,185$133.15$157,782.75View SEC Filing  
8/11/2014Jeffrey K TobiasCMOSell4,933$135.42$668,026.86View SEC Filing  
7/8/2014Bruce C CozaddCEOSell5,000$155.00$775,000.00View SEC Filing  
7/8/2014Suzanne Sawochka HooperEVPSell1,853$155.00$287,215.00View SEC Filing  
7/7/2014Karen J WilsonSVPSell2,500$165.00$412,500.00View SEC Filing  
6/25/2014Seamus MulliganDirectorSell50,000$149.69$7,484,500.00View SEC Filing  
6/20/2014Russell J CoxCOOSell2,000$155.00$310,000.00View SEC Filing  
6/17/2014Fintan KeeganEVPSell3,750$150.00$562,500.00View SEC Filing  
6/10/2014Bruce C CozaddCEOSell5,000$142.34$711,700.00View SEC Filing  
5/16/2014Jeffrey TobiasCMOSell1,000$128.01$128,010.00View SEC Filing  
5/13/2014Bruce CozaddCEOSell5,000$128.92$644,600.00View SEC Filing  
4/17/2014Rick WinninghamDirectorSell27,500$140.00$3,850,000.00View SEC Filing  
4/14/2014Jeffrey TobiasCMOSell3,000$128.54$385,620.00View SEC Filing  
4/8/2014Bruce CozaddCEOSell5,000$123.18$615,900.00View SEC Filing  
3/10/2014Jeffrey TobiasCMOSell3,000$152.99$458,970.00View SEC Filing  
3/6/2014Fintan KeeganEVPSell4,640$159.90$741,936.00View SEC Filing  
3/4/2014Seamus MulliganDirectorSell550,000$156.25$85,937,500.00View SEC Filing  
3/3/2014Patrick EnrightDirectorSell559,628$152.39$85,281,710.92View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Latest Headlines for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Source:
DateHeadline
nasdaq.com logoBridges Investment Management Inc Buys Bristol-Myers Squibb Company, Bristol-Myers Squibb ...
www.nasdaq.com - July 22 at 11:09 PM
americanbankingnews.com logoSuzanne Sawochka Hooper Sells 4,580 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock
www.americanbankingnews.com - July 21 at 7:30 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 18 at 10:34 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) EVP Sells $30,994.00 in Stock
www.americanbankingnews.com - July 18 at 7:53 PM
americanbankingnews.com logoLipoScience (LPDX) and Jazz Pharmaceuticals PLC (JAZZ) Critical Contrast
www.americanbankingnews.com - July 18 at 6:10 PM
americanbankingnews.com logoDeutsche Bank AG Increases Jazz Pharmaceuticals PLC (JAZZ) Price Target to $178.00
www.americanbankingnews.com - July 17 at 7:14 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - July 15 at 9:44 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given "Buy" Rating at Cowen and Company
www.americanbankingnews.com - July 15 at 8:14 AM
finance.yahoo.com logoETFs with exposure to Jazz Pharmaceuticals Plc : July 14, 2017
finance.yahoo.com - July 15 at 3:23 AM
finance.yahoo.com logoJazz Pharmaceuticals Plc – Value Analysis (NASDAQ:JAZZ) : July 12, 2017
finance.yahoo.com - July 13 at 4:14 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Expected to Post Quarterly Sales of $408.14 Million
www.americanbankingnews.com - July 12 at 9:36 AM
seekingalpha.com logoWhat Lies Ahead For Pharma ETFs In Second Half 2017
seekingalpha.com - July 12 at 12:18 AM
finance.yahoo.com logoJazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : July 11, 2017
finance.yahoo.com - July 12 at 12:18 AM
americanbankingnews.com logoZacks: Analysts Expect Jazz Pharmaceuticals PLC (JAZZ) Will Announce Earnings of $1.85 Per Share
www.americanbankingnews.com - July 10 at 8:10 PM
nasdaq.com logoWhat Lies Ahead for Pharma ETFs in Second Half 2017 - Nasdaq
www.nasdaq.com - July 10 at 8:05 PM
bloomberg.com logoRare-Disease Drugmakers Join in Worries Over GOP Health ... - Bloomberg
www.bloomberg.com - July 7 at 6:37 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) PT Raised to $175.00 at Janney Montgomery Scott
www.americanbankingnews.com - July 4 at 8:28 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Rating Lowered to Neutral at Mizuho
www.americanbankingnews.com - July 4 at 8:28 PM
americanbankingnews.com logoDeutsche Bank AG Reiterates Buy Rating for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
www.americanbankingnews.com - July 4 at 8:26 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Price Target Raised to $170.00 at Leerink Swann
www.americanbankingnews.com - July 4 at 8:26 PM
finance.yahoo.com logoWhy Is Barclays Optimistic about Jazz Pharmaceuticals?
finance.yahoo.com - June 30 at 8:13 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Short Interest Update
www.americanbankingnews.com - June 30 at 7:06 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Upgraded to Buy at Vetr Inc.
www.americanbankingnews.com - June 28 at 12:38 AM
nasdaq.com logoAVEO's Kidney Cancer Candidate Gets CHMP Recommendation ... - Nasdaq
www.nasdaq.com - June 27 at 6:15 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Given Buy Rating at Cantor Fitzgerald
www.americanbankingnews.com - June 27 at 8:06 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) EVP Suzanne Sawochka Hooper Sells 420 Shares
www.americanbankingnews.com - June 26 at 10:40 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 23 at 8:36 PM
finance.yahoo.com logoJazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : June 22, 2017
finance.yahoo.com - June 22 at 12:58 PM
reuters.com logoBRIEF-Jazz Pharmaceuticals Plc says CEO's 2016 compensation was $8.8 million - Reuters
www.reuters.com - June 21 at 4:56 AM
bizjournals.com logoMyelodysplastic Syndrome Pipeline Therapeutic Drugs and Companies Review H1 2017 Research Report Available at RnRMarketResearch
www.bizjournals.com - June 20 at 11:55 PM
reuters.com logoBRIEF-Jazz Pharmaceuticals Plc says CEO's 2016 compensation was $8.8 million
www.reuters.com - June 20 at 6:55 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - June 20 at 6:38 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) EVP Michael Patrick Miller Sells 200 Shares
www.americanbankingnews.com - June 16 at 7:58 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Jazz Pharmaceuticals PLC (JAZZ) to Announce $1.85 Earnings Per Share
www.americanbankingnews.com - June 14 at 6:20 PM
nasdaq.com logoWhy Is Jazz Pharmaceuticals (JAZZ) Down 3.3% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - June 13 at 5:49 PM
finance.yahoo.com logoWhy Is Jazz Pharmaceuticals (JAZZ) Down 3.3% Since the Last Earnings Report?
finance.yahoo.com - June 13 at 10:46 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC's (JAZZ) "Overweight" Rating Reaffirmed at J P Morgan Chase & Co
www.americanbankingnews.com - June 12 at 4:54 PM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Upgraded at BidaskClub
www.americanbankingnews.com - June 10 at 7:58 PM
finance.yahoo.com logoJazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : June 9, 2017
finance.yahoo.com - June 9 at 9:27 AM
finance.yahoo.com logoJazz Pharma Sleep Disorder Candidate Positive in Phase III
finance.yahoo.com - June 7 at 5:37 PM
americanbankingnews.com logoBMO Capital Markets Reiterates "Outperform" Rating for Jazz Pharmaceuticals plc - (JAZZ)
www.americanbankingnews.com - June 7 at 12:22 PM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Given Outperform Rating at Cowen and Company
www.americanbankingnews.com - June 7 at 10:58 AM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Earns Overweight Rating from Piper Jaffray Companies
www.americanbankingnews.com - June 7 at 10:58 AM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Upgraded to Buy by Vetr Inc.
www.americanbankingnews.com - June 7 at 12:56 AM
streetinsider.com logoJazz Pharmaceuticals (JAZZ) Presents Data for Phase 3 TONES 2 Study of JZP-110 to Treat Excessive Sleepiness
www.streetinsider.com - June 6 at 11:36 PM
prnewswire.com logoJazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness ... - PR Newswire (press release)
www.prnewswire.com - June 6 at 6:36 PM
finance.yahoo.com logoJazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy
finance.yahoo.com - June 6 at 6:36 PM
finance.yahoo.com logoJazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea
finance.yahoo.com - June 6 at 6:36 PM
americanbankingnews.com logoRick E. Winningham Sells 5,000 Shares of Jazz Pharmaceuticals plc - (JAZZ) Stock
www.americanbankingnews.com - June 2 at 7:51 PM
nasdaq.com logoJazz Pharmaceuticals' Vyxeos NDA Granted Priority Review
www.nasdaq.com - June 1 at 6:51 PM

Social

Chart

Jazz Pharmaceuticals PLC (JAZZ) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by MarketBeat.com Staff